Jamie Cohen, MD
Interventional Cardiology · Middleburg Heights, OHNPI 1376576215
Payments from drug & device makers
Across 322 payments — averaging $35.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- Abiomed$2K
- Medtronic$1K
- Novartis$863
- Pfizer$479
- Boston Scientific$445
- plus $4K from 34 others
What the payments were for
- Consulting fees$100%
- Travel & lodging$2,64723%
- Food & beverage$8,83277%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 8 | $2,575 |
| Abiomed | 18 | $1,890 |
| Medtronic | 24 | $1,352 |
| Novartis | 40 | $863 |
| Pfizer | 32 | $479 |
| Boston Scientific | 13 | $445 |
| Abbott | 8 | $409 |
| Atricure, Inc. | 18 | $352 |
| E.r. Squibb & Sons, L.L.C. | 22 | $339 |
| Shockwave Medical, Inc | 2 | $336 |
| Johnson & Johnson | 21 | $285 |
| AstraZeneca | 17 | $280 |
| Sanofi-aventis U.S. LLC | 13 | $203 |
| Boehringer Ingelheim | 11 | $196 |
| Cardiovascular Systems Inc. | 6 | $191 |
| Amgen | 10 | $179 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $167 |
| Amarin Pharma, Inc. | 6 | $108 |
| Merck | 6 | $103 |
| Esperion Therapeutics, Inc. | 5 | $94 |
| Terumo Medical Corporation | 2 | $74 |
| Novo Nordisk | 2 | $59 |
| Philips North America LLC | 3 | $56 |
| Teleflex LLC | 3 | $46 |
| Cordis US CORP. | 2 | $46 |
| Impulse Dynamics (USA) Inc. | 2 | $41 |
| Lundbeck LLC | 3 | $40 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $37 |
| Inquis Medical, Inc. | 1 | $30 |
| Edwards Lifesciences | 1 | $28 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Surmodics, Inc. | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Elutia, Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $13 |
| Chiesi USA, Inc. | 1 | $11 |
| Z-medica, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$3,097
- Impella$1,398
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$336
- ONYX FRONTIER$318
- OPTIS$171
- Penumbra Ruby Coil$161
- Penumbra System$152
- AVVIGO Guidance System$148
- Euphora$100
- ONYX 18$100
- Diamondback Coronary$100
How this compares
$11,489 in reported general payments places this provider in the 60th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 533 | $559,576 |
| XareltoRivaroxaban | 274 | $318,462 |
| EntrestoSacubitril/Valsartan | 62 | $63,728 |
| Repatha SureclickEvolocumab | 54 | $63,599 |
| BrilintaTicagrelor | 56 | $36,084 |
| JardianceEmpagliflozin | 26 | $30,788 |
| FarxigaDapagliflozin Propanediol | 29 | $28,151 |
| Praluent PenAlirocumab | 21 | $14,702 |
| Metoprolol Succinate | 742 | $12,803 |
| Atorvastatin Calcium | 747 | $9,121 |
| JanuviaSitagliptin Phosphate | 12 | $6,500 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $5,183 |
| Digoxin | 151 | $4,499 |
| Metoprolol Tartrate | 632 | $3,993 |
| ClopidogrelClopidogrel Bisulfate | 301 | $3,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $479 | $559,576533 claims |
| Johnson & JohnsonXarelto | $285 | $318,462274 claims |
| AstraZenecaBrilinta, Farxiga | $280 | $64,23585 claims |
| NovartisEntresto | $863 | $63,72862 claims |
| Boehringer IngelheimJardiance | $196 | $30,78826 claims |
| MerckJanuvia | $103 | $6,50012 claims |
| Esperion Therapeutics, Inc.Nexlizet | $94 | $5,18312 claims |
| Sanofi-aventis U.S. LLCPlavix | $203 | $2,90612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Middleburg Heights
- Santiago GarciaCincinnati$3.6M
- Gary AnselColumbus$3.4M
- Dean KereiakesCincinnati$3.4M
- Steven YakubovColumbus$3.2M
- Joseph ChooCincinnati$1.9M
- Carlos Sanchez SotoColumbus$1.7M
- John CheathamColumbus$1.7M
- Brendan DuffyCanton$1.5M
- Timothy HenryCincinnati$1.3M
- Gary FishbeinCenterville$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.